Gustave Roussy, Université Paris-Saclay, Inserm UMR1015, France; Gustave Roussy, Université Paris-Saclay, Département D'imagerie Médicale, Villejuif F-94805, France; Department of Radiology, Columbia University Medical Center, New York Presbyterian Hospital, New York, NY, USA.
Gustave Roussy, Université Paris-Saclay, Département D'imagerie Médicale, Villejuif F-94805, France.
Eur J Cancer. 2018 Mar;91:136-144. doi: 10.1016/j.ejca.2017.12.015.
We aimed to define the depth and time of maximal anti-tumour response to programmed death-1 blockade antibodies (anti-PD1) in heavily pre-treated patients with classical Hodgkin lymphoma (HL). To this end, we evaluated the kinetics of response for up to two years.
The 18F-FDG positron-emission tomography (PET) and contrast-enhanced computerised tomography (CECT) data of all relapsed or refractory HL treated at Gustave Roussy, Villejuif, France, from 2013 to 2015 were retrospectively reviewed according to the International Harmonisation Project Cheson 2014 criteria and the LYmphoma Response to Immunomodulatory therapy Criteria (LYRIC).
Sixteen patients were included. The median (range) treatment duration was 18.4 (2.8-23.7) months. Fifty-six percent of patients (9/16) achieved an objective response at 3 months, including 19% (3/16) of complete response. Seventeen percent (1/6) of partial responders at 3 months were converted in a complete response. 22% (2/9) of responders at 3 months relapsed before one year. The nadir was reached at 12.7 (3.0-23.0) months. The median (range) depth of response at nadir was -77% (-50% to 100%).
We concluded that complete metabolic responses occurred within 6 months, a minority of partial responses were converted in complete response, and the median nadir was observed one year after treatment initiation. These data could help to better define the optimal treatment strategy by PET or CECT-directed approaches.
我们旨在确定在经过大量预处理的经典霍奇金淋巴瘤（HL）患者中，程序性死亡-1 阻断抗体（抗 PD1）的抗肿瘤反应的深度和时间。为此，我们评估了长达两年的反应动力学。
根据国际协调项目 Cheson 2014 标准和 LYmphoma Response to Immunomodulatory therapy Criteria（LYRIC），回顾性分析了 2013 年至 2015 年在法国古斯塔夫·鲁西研究所（Gustave Roussy，Villejuif）接受治疗的所有复发或难治性 HL 的 18F-FDG 正电子发射断层扫描（PET）和对比增强计算机断层扫描（CECT）数据。
共纳入 16 例患者。中位（范围）治疗持续时间为 18.4（2.8-23.7）个月。56%（9/16）的患者在 3 个月时获得客观缓解，其中 19%（3/16）的患者完全缓解。3 个月时部分缓解的患者中有 17%（1/6）转换为完全缓解。3 个月时的 22%（2/9）缓解患者在一年内复发。最低点在 12.7（3.0-23.0）个月达到。最低点时的中位（范围）反应深度为-77%（-50%至 100%）。
我们得出结论，完全代谢反应发生在 6 个月内，少数部分反应转换为完全反应，中位最低点在治疗开始后 1 年出现。这些数据可以帮助通过 PET 或 CECT 指导的方法更好地定义最佳治疗策略。
